On the basis of this evidence, we hypothesized that specific inhibitor(s) of the interaction between S349-phosphorylated p62 and Keap1 would recover the ability of Keap1 to bind to Nrf2, and possibly function as an anti-tumour drug for HCC (Fig. 9a). Here, KEAP1 is linked to neoplasm.